Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment

The ability for cells to harness alternative splicing enables them to diversify their proteome in order to carry out complex biological functions and adapt to external and internal stimuli. The spliceosome is the multiprotein-RNA complex charged with the intricate task of alternative splicing. Aberr...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 868664
Main Authors Murphy, Anthony J, Li, Alex H, Li, Peichao, Sun, Hong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 08.04.2022
Subjects
alternative splicing
cancer therapeutics
Oncology
RNA splicing
spliceosome inhibitors
splicing factors
cancer therapeutics
splicing factors
alternative splicing
spliceosome inhibitors
RNA splicing
Online AccessGet full text

Cover

More Information
Summary:The ability for cells to harness alternative splicing enables them to diversify their proteome in order to carry out complex biological functions and adapt to external and internal stimuli. The spliceosome is the multiprotein-RNA complex charged with the intricate task of alternative splicing. Aberrant splicing can arise from abnormal spliceosomes or splicing factors and drive cancer development and progression. This review will provide an overview of the alternative splicing process and aberrant splicing in cancer, with a focus on serine/arginine-rich (SR) proteins and their recently reported roles in cancer development and progression and beyond. Recent mapping of the spliceosome, its associated splicing factors, and their relationship to cancer have opened the door to novel therapeutic approaches that capitalize on the widespread influence of alternative splicing. We conclude by discussing small molecule inhibitors of the spliceosome that have been identified in an evolving era of cancer treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Jose J.G. Marin, University of Salamanca, Spain; Zhaohui Feng, The State University of New Jersey, United States
Edited by: Bruce Zetter, Harvard Medical School, United States
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.868664